
IGF-1 LR3 1mg
Research-grade IGF-1 LR3 (Long R3 IGF-1) 1mg, a lyophilised 83-amino-acid insulin-like growth factor-1 analogue with reduced IGFBP binding, for laboratory research use only. COA-backed, Australia-wide Express Post.
RetaLABS IGF-1 LR3 1mg is supplied as a single lyophilised vial of Long R3 Insulin-like Growth Factor-1 (Long Arg3 IGF-1), an 83-amino-acid analogue of human IGF-1. A 13-residue N-terminal extension and an arginine-for-glutamate substitution at position 3 sharply reduce the peptide's affinity for the insulin-like growth factor binding proteins (IGFBPs), leaving more free peptide available to activate the IGF-1 receptor and giving IGF-1 LR3 a longer functional half-life and greater potency than native IGF-1 in cell-culture systems.
Research using IGF-1 LR3 centres on the IGF-1 receptor (IGF-1R) tyrosine kinase and its downstream PI3K/Akt and Ras/MAPK cascades, which drive cell proliferation, differentiation and protein synthesis. It is a long-established supplement in myoblast, satellite-cell and hepatocyte culture models, and in the wider study of growth-factor signalling and its cross-talk with the growth hormone axis. RetaLABS stocks research-grade IGF-1 LR3 in 1mg lyophilised vials for laboratory research use only.
For how IGF-1 relates to exogenous growth hormone, see the HGH vs IGF-1 research comparison and the HGH Research Guide. Growth hormone secretagogues that modulate the IGF-1 axis upstream are covered in the CJC-1295 / Ipamorelin Research Guide. For reconstitution and storage, see the Peptide Reconstitution and Storage Guide, and for the Australian research framework the Research Peptides Legal Status guide.
Frequently Asked Questions
Everything you need to know about IGF-1 LR3 1mg